版本:
中国

BRIEF-Theravance Biopharma highlights filing of U.S. new drug application for the closed triple in COPD by Glaxosmithkline and Innoviva

Nov 21 Theravance Biopharma Inc -

* Theravance Biopharma highlights filing of U.S. new drug application for the closed triple in COPD by Glaxosmithkline and Innoviva

* GSKon track for European regulatory submission for closed triple in COPD by end of 2016

* Results of impact study are expected to be reported by GSK in 2017

* Regulatory filing in EU is planned in coming weeks,is expected to be followed by submissions in other countries beginning in 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐